The drug, aducanumab, made by Biogen, would be the first new Alzheimer’s treatment in nearly two decades. But the advisory panel said there was not enough evidence of its effectiveness in slowing cognitive decline.
ASU, TGen, and Banner researchers discover a link between a chronic gut infection and the development of Alzheimer’s disease
Arizona State University and Banner Alzheimer’s Institute researchers, along with their collaborators, have discovered a surprising link between a chronic gut infection caused by a common virus and the development of Alzheimer’s disease in a subset of people. Click...